LUXEMBURG–(BUSINESS WIRE)– Eurofins Technologies (Parijs:ERF) kondigt de lancering aan van de multiplex RT-PCR-test GSD NovaType Detect + Select K417N SARS-CoV-2. Binnen slechts een week sinds de eerste rapporten over de zorgwekkende Omicron-variant, is deze kit ontwikkeld als een snelle reactie om de aanwezigheid ervan te identificeren. De test is ontworpen voor de gelijktijdige kwalitatieve detectie van SARS-CoV-2 genomisch RNA en identificatie van de spike (S)-mutatie K417N in één reactie.

De resultaten van deze RT-PCR-assay kunnen binnen 1 uur worden verkregen, waardoor het een snelle en kosteneffectieve oplossing is om de aanwezigheid van de Omicron-variant te identificeren voordat monsters worden bevestigd door middel van sequencing van het hele genoom.

Eurofins Technologies werkt voortdurend aan het aanpassen van haar productaanbod om de uitdagingen van de aanhoudende COVID-19-pandemie het hoofd te bieden.

Eurofins Technologies Launches a New Multiplex RT-PCR Assay for Combined SARS-CoV-2 Screening and Rapid Detection of the Omicron (B.1.1.529) Variant of Concern

LUXEMBOURG–(BUSINESS WIRE)– Eurofins Technologies (Paris:ERF) announces the launch of the multiplex RT-PCR assay GSD NovaType Detect + Select K417N SARS-CoV-2. Within just one week since the first reports on the Omicron variant of concern, this kit has been developed as a quick response to identify its presence. The assay is designed for the simultaneous qualitative detection of SARS-CoV-2 genomic RNA and identification of the spike (S) mutation K417N in one reaction.

The results of this RT-PCR assay can be obtained within 1 hour, which makes it a fast and cost-effective solution to identifying the presence of the Omicron variant before samples are confirmed by whole genome sequencing.

Eurofins Technologies is constantly working to adapt its product offering to meet the challenges of the ongoing COVID-19 pandemic..

For more information, please visit Eurofins Technologies website.

About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211203005288/en/

Contacts

Rodrigo Berlie

ir@eurofins.com